HNHA
HNHA is a potent HDAC inhibitor with an IC50 of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer[1].
Product Specifications
CAS Number
926908-04-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HDAC; HIF/HIF Prolyl-Hydroxylase; MMP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hnha.html
Purity
99.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NO)CCCCCCSC1=CC=C2C=CC=CC2=C1
Molecular Formula
C17H21NO2S
Molecular Weight
303.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Park KC, et al. Potential anti-cancer activity of N-hydroxy-7- (2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011 Feb;102 (2) :343-50.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MMP-2; MMP-9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB3284-100 1x 100 µL
Tyrosinase-Related Protein-1 (TYRP-1) (Melanoma Marker) (TYRP1/3284), 0.2mg/mL
Sign In for Pricing
View Details 
